Candel Therapeutics
Develops viral immunotherapies for solid tumors through adenovirus and HSV platforms.
$13.07
After-hours close+0.01 (+0.08%)
At close$13.06(−5.02%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.30 | — | — |
| Aug 2026 | −$0.24 | −$0.52 | −118.6% |
| May 2026 | −$0.22 | −$0.14 | +36.4% |
| Mar 2026 | −$0.24 | −$0.54 | −125.0% |
| Nov 2025 | −$0.17 | −$0.21 | −23.5% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Sep 2021 | |||
| Jul 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | −$0.30 | — | — | — | — | — |
| Aug 13, 2026 | −$0.24 | −$0.52 | −118.6% | — | — | — |
| May 14, 2026 | −$0.22 | −$0.14 | +36.4% | — | — | — |
| Mar 12, 2026 | −$0.24 | −$0.54 | −125.0% | — | — | — |
| Nov 13, 2025 | −$0.17 | −$0.21 | −23.5% | — | — | — |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | ||||||
| Aug 14, 2025 | ||||||
| May 13, 2025 | ||||||
| Mar 13, 2025 | ||||||
| Nov 14, 2024 | ||||||
| Aug 13, 2024 | ||||||
| May 14, 2024 | ||||||
| Mar 28, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Aug 10, 2023 | ||||||
| May 11, 2023 | ||||||
| Mar 30, 2023 | ||||||
| Nov 10, 2022 | ||||||
| Aug 5, 2022 | ||||||
| May 12, 2022 | ||||||
| Mar 29, 2022 | ||||||
| Nov 12, 2021 | ||||||
| Sep 8, 2021 | ||||||
| Jul 28, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||